¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"dose rate variation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • high dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • immunizing dose
    ¸é¿ª¿ë·®, ¸é¿ª·®
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • infective dose
    °¨¿°¿ë·®, °¨¿°·®
  • integral dose
    ÀûºÐ¼±·®
  • lethal dose
    1. Ä¡»ç¿ë·® 2. Ä¡»ç¼±·®
  • loading dose
    ºÎÇϿ뷮, ºÎÇÏ·®
  • low-dose tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • maintenance dose
    À¯Áö¿ë·®
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal infecting dose
    ÃÖ¼Ò°¨¿°¿ë·®
  • minimal lethal dose
    1. ÃÖ¼ÒÄ¡»ç·® 2. ÃÖ¼ÒÄ¡»ç¼±·®
  • minimum dose
    1. ÃÖ¼Ò¿ë·® 2. ÃÖ¼Ò¼±·®
  • maximum allowable dose
    ÃÖ´ëÇã¿ë·®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • heart rate
    ½ÉÀå¹Úµ¿¼ö
  • infant mortality rate
    ¿µ¾Æ»ç¸Á·ü
  • morbidity rate
    ÀÌȯ·ü
  • mortality rate
    »ç¸Á·ü
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • onset rate
    ¹ß»ý·ü
  • operative mortality rate
    ¼ö¼ú»ç¸Á·ü
  • peak expiratory flow rate
    ÃÖ°í³¯¼û¼Óµµ, ÃÖ°íÈ£±âÀ¯¼Ó
  • perfusion rate
    °ü·ù¼Óµµ, °ü·ùÀ²
  • pregnancy rate
    Àӽŷü
  • prevalence rate
    À¯º´·ü
  • pulse rate
    ¸Æ¹Ú¼ö
  • relaxation rate
    À̿Ϸü
  • respiratory rate
    È£Èí¼öÈ£Èí·ü
  • response rate
    ¹ÝÀÀ·ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • doubling dose
    ¹è°¡¼±·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • erythema dose
    È«¹Ý¼±·®
  • exit dose
    Åë°ú¼±·®
  • exposure dose
    Æø·Î¼±·®
  • fatal dose
    Ä¡»ç¿ë·®, Ä¡»ç¼±·®
  • fractional dose
    ºÐÇÒ¿ë·®, ºÐÇÒ¼±·®
  • immunizing dose
    ¸é¿ª¿ë·®, ¸é¿ª·®
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • infective dose
    °¨¿°¿ë·®, °¨¿°·®
  • integral dose
    Àû»ê¹æ»ç¼±·®
  • lethal dose
    Ä¡»ç¿ë·®, Ä¡»ç·®, Ä¡»ç¼±·®
  • loading dose
    ºÎÇϿ뷮, ºÎÇÏ·®
  • maintenance dose
    À¯Áö¿ë·®
  • maximum dose
    ÃÖ´ë¿ë·®, ÃÖ´ë¼±·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • gonadal dose
    »ý½Ä¼±¼±·®
  • half lethal dose
    ¹ÝÄ¡»ç·®(ÚâöÈÞÝåÖ).
  • head drop dose =HD
    µÎºÎ Ãß¶ô·®(¡­õÍÕªåÖ).
  • heat dose equivalent
    ¿­¼±·®´ç·®
  • high dose tolerance
    °ú·®°ü¿ë
  • immunizing dose
    ¸é¿ª·®(Øóæ¹åÖ).
  • incident dose
    ÀԻ缱·®
  • ineffective dose
    ¹«È¿·®(ÙíüùåÖ).
  • infectious(-tive) dose
    °¨¿°À¯¹ß·®
  • infective dose
    °¨¿° À¯¹ß·®
  • priming dose
    ÃÊȸ·®, ÃæÁø·®
  • priming dose
    ÃÊȸ°¨ÀÛ ¿ë·®
  • priming dose
    ÃÊȸÇ׿øÀڱط®.(¾à¸®)ÃÊȸ(¿ë)·®.
  • priming dose
    ÃÊȸÇ׿øÀڱط®.[¾à¸®]ÃÊȸ(¿ë)·®, ºÎÇÏ(¿ë)·®.
  • quasithreshold dose, Dq
    ÁØÇѰ輱·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • intrapair variation
    ½Ö»ý¾Æ°£º¯ÀÌ(äªßæä® Êàܨì¶).
  • leukocyte variation
    ¹éÇ÷±¸º¯µ¿
  • magnetic susceptibility variation
    ÀÚ±âÈ­À² º¯ÀÌ
  • monophasic variation
    ´Ü»ó¼º º¯È­(Ó¤ßÓàõܨ ûù).
  • pelvic variation
    °ñ¹Ýº¯Çü.
  • phase variation
    »óº¯ÀÌ
  • phenotypic variation
    Ç¥Çöº¯ÀÌ(¡­Ü¨ì¶).
  • phenotypic variation
    Ç¥Çöº¯ÀÌ(¡­Ü¨ì¶).
  • physiologic variation
    »ý¸®Àû º¯µ¿<º¯ÀÌ>
  • range of variation
    º¯ÀÌÆø.
  • singular variation
    ´Üº¯ÀÌ(ËÀËÒËö).
  • total variation
    Àüº¯µ¿(îïܨÔÑ).
  • variation
    º¯ÀÌ
  • variation
    º¯ÀÌ
  • variation curve
    º¯À̰(ܨì¶ÍØàÊ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • permissible dose
    Çã¿ë·®(úÉé»Õá)
  • priming dose
    ÀÏÂ÷󸮿뷮(ìéó­ô¥×âéÄÕá)
  • radiation absorbed dose
    ¹æ»ç¼± Èí¼ö·®(Û¯ÞÒàÊýåâ¥Õá)
  • radiation dose
    ¹æ»ç¼±·®(Û¯ÞÒàÊÕá)
  • threshold dose
    ¹®ÅÎ ¼±·®(àÊÕá)
  • tissue culture infectious dose
    Á¶Á÷¹è¾ç °¨¿°·® (ðÚòÄÛÆå×ÊïæøÕá)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
PINV postimperative negative variation
TCNV terminal contingent negative variation
Var, var variable; variant, variation, variety
ACR abnormally contracting region; absolute catabolic rate; acriflavine; adenomatosis of colon and rectu...
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
% CV variation
BMD Benchmark dose
BED Biologically Effective Dose
CTDI Computed Tomography Dose Index
DDD Defined Daily Dose
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • maximum accumulation dose
    ÃÖ´ë ÃàÀû·®
  • maximum tolerance dose
    ÃÖ´ë ³»¿ë·®, ÃÖ´ë °ßµõ ¼±·®
  • mean effective dose
    50% À¯È¿·®
  • mean lethal dose
    50% Ä¡»ç·®
  • mean target dose
    Æò±Õ Ç¥Àû ¼±·®
  • metered-dose inhaler

    methacholine (¸ÞŸÄݸ°

    °­·ÂÇÑ Äݸ° ÀÛµ¿Á¦·Î¼­ ¾Æ¼¼Æ¿Äݸ°°ú °°Àº ÀÛ¿ëÀÌ ÀÖ´Ù.
  • midbreast dose
    À¯¹æ Áß¾Ó Á¶»ç¼±·®
  • minimal dose
    ÃÖ¼Ò·®
  • minimum dose
    ÃÖ¼Ò·®
  • minimum hemolytic dose
    ÃÖ¼Ò ¿ëÇ÷·®
  • minimum inhibitory dose
    ÃÖ¼Ò ¾ïÁ¦·®
  • minimum reacting dose
    ÃÖ¼Ò ¹ÝÀÀ·®
  • optimal dose
    ÃÖÀû·®, ÀûÁ¤·®
  • oral dose
    ±¸°­ ¿ë·®
  • organ tolerance dose
    ±â°ü Çã¿ë·®, Àå±â Çã¿ë·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
dose-response relationship, radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
(12 Dec 1998)
immunologic high dose tolerance Induction of tolerance by exposure to large amounts of protein antigens.
(05 Mar 2000)
initial dose A comparatively large dose given at the beginning of treatment to get the patient under the influence of the drug.
Synonym: loading dose.
(05 Mar 2000)
integral dose The total energy absorbed by the body, the product of the mass of tissue irradiated and the absorbed dose; unit, the gram rad.
(05 Mar 2000)
optimum dose The dose of a drug or radiation that will produce the desired effect with minimum likelihood of undesirable symptoms.
(05 Mar 2000)
therapeutic dose The quantity of any substance required to effect the cure of a disease or that will correct the manifestations of a deficiency of a particular factor in the diet, effective dose used with therapeutically applied compounds.
Synonym: therapeutic dose.
(05 Mar 2000)
effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
tissue culture infectious dose The quantity of a cytopathogenic agent, such as a virus, that will produce a cytopathic effect in 50% of the cultures inoculated.
(05 Mar 2000)
tolerance dose The largest dose of a remedy that can be accepted without the production of injurious symptoms.
(05 Mar 2000)
equianalgesic dose The qualitative ratio between actual milligram potency of comparable analgesics required to achieve the equivalent therapeutic effect.
(05 Mar 2000)
equivalent dose In radiation protection, the absorbed dose averaged over a tissue or organ and weighted for the quality of the radiation of interest. The unit of equivalent dose is the sievert.
(05 Mar 2000)
erythema dose The minimum amount of X-rays or other form of radiation sufficient to produce erythema; historically, this dose was indicated by the Sabouraud meter as the B tint, the Holzknecht as 5(5H), the Hampson as 4, and the Kienbock as 10.
(05 Mar 2000)
exit dose The exposure dose of radiation leaving a body opposite the portal of entry.
(05 Mar 2000)
exposure dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
unit dose Occurring in or using a single dose, seen as a standard of measurement.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • rate meter
    (°è¼ö±âÀÇ)°è¼öÀ²°è
  • rediscount rate
    (¾îÀ½ÀÇ)ÀçÇÒÀÎÀ²
  • second rate
    2·ùÀÇ;2µîǰ;...¸¸ ¸øÇÑ
  • second rate
    2·ùÀÇ;¿­µîÇÑ;Æò¹üÇÑ
  • third rate
    3µîÀÇ;¿­µîÇÑ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á